Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA
Phase of Trial: Phase IV
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GLORIA
- Sponsors AstraZeneca
- 11 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Dec 2017.
- 11 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Dec 2017.
- 10 Jun 2017 Biomarkers information updated